PA
MPLT

Perceptive Advisors’s MapLight Therapeutics MPLT Stock Holding History

Perceptive Advisors’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-550,000
Closed -$9.66M – 136
2025
Q4 		$9.66M Buy
+550,000
New +$9.21M 0.17% 81

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors's MPLT Position: Q1 2026 in Review

Perceptive Advisors sold out of MapLight Therapeutics (MPLT) in Q1 2026, closing a stake of 550,000 shares — an estimated $9.66M sold.

Perceptive Advisors first reported a position in MPLT in Q4 2025 and held it in 1 quarter. The position peaked at $9.66M in Q4 2025. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

  • Perceptive Advisors reported no remaining MapLight Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Perceptive Advisors sold 550,000 MapLight Therapeutics shares in Q1 2026, an estimated $9.66M.
  • Perceptive Advisors first reported a position in MapLight Therapeutics in Q4 2025 and held it in 1 quarter.
  • Perceptive Advisors's MapLight Therapeutics position peaked at $9.66M in Q4 2025.
  • 81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.